Disulfiram in glioma: Literature review of drug repurposing

Shiyu Zhong; Shengyu Liu; Xin Shi; Xin Shi; Xudong Zhang; Kunhang Li; Guojun Liu; Lishuai Li; Shanwei Tao; Bowen Zheng; Weichen Sheng; Ziyin Ye; Qichen Xing; Qingqing Zhai; Lijie Ren; Ying Wu; Yijun Bao

doi:10.3389/fphar.2022.933655

Frontiers in Pharmacology (Aug 2022)

Disulfiram in glioma: Literature review of drug repurposing

Shiyu Zhong,
Shengyu Liu,
Xin Shi,
Xin Shi,
Xudong Zhang,
Kunhang Li,
Guojun Liu,
Lishuai Li,
Shanwei Tao,
Bowen Zheng,
Weichen Sheng,
Ziyin Ye,
Qichen Xing,
Qingqing Zhai,
Lijie Ren,
Ying Wu,
Yijun Bao

Affiliations

Shiyu Zhong: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Shengyu Liu: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Xin Shi: School of Maths and Information Science, Shandong Technology and Business University, Yantai, China
Xin Shi: Business School, All Saints Campus, Manchester Metropolitan University, Manchester, United Kingdom
Xudong Zhang: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Kunhang Li: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Guojun Liu: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Lishuai Li: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Shanwei Tao: Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China
Bowen Zheng: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Weichen Sheng: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Ziyin Ye: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Qichen Xing: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China
Qingqing Zhai: School of Management, Shanghai University, Shanghai, China
Lijie Ren: Neurology Department of Shenzhen Second People’s Hospital/ First Affiliated Hospital of Shenzhen, University Health Science Center, Shenzhen, China
Ying Wu: Department of General Practice, The First Hospital, China Medical University, Shenyang, China
Yijun Bao: Department of Neurosurgery, The Fourth Hospital of China Medical University, Huanggu, Shenyang, China

DOI: https://doi.org/10.3389/fphar.2022.933655
Journal volume & issue: Vol. 13

Abstract

Read online

Gliomas are the most common malignant brain tumors. High-grade gliomas, represented by glioblastoma multiforme (GBM), have a poor prognosis and are prone to recurrence. The standard treatment strategy is tumor removal combined with radiotherapy and chemotherapy, such as temozolomide (TMZ). However, even after conventional treatment, they still have a high recurrence rate, resulting in an increasing demand for effective anti-glioma drugs. Drug repurposing is a method of reusing drugs that have already been widely approved for new indication. It has the advantages of reduced research cost, safety, and increased efficiency. Disulfiram (DSF), originally approved for alcohol dependence, has been repurposed for adjuvant chemotherapy in glioma. This article reviews the drug repurposing method and the progress of research on disulfiram reuse for glioma treatment.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords